Clearmind Medicine, Inc. (CMND)
5.76
-0.24
(-4.00%)
USD |
NASDAQ |
Oct 06, 12:18
Clearmind Medicine Cash from Investing (Quarterly) : -0.7625M for July 31, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2026 | -0.7625M |
| April 30, 2026 | -0.6541M |
| January 31, 2026 | 0.00 |
| October 31, 2025 | -0.529M |
| July 31, 2025 | 0.1126M |
| April 30, 2025 | -0.20M |
| January 31, 2025 | 0.0695M |
| October 31, 2024 | |
| July 31, 2024 | 0.0333M |
| April 30, 2024 | 0.0783M |
| January 31, 2024 | 0.00 |
| October 31, 2023 | -0.0338M |
| July 31, 2023 | 0.0078M |
| April 30, 2023 | 0.00 |
| January 31, 2023 | 0.00 |
| October 31, 2022 | 0.0436M |
| July 31, 2022 | -0.0493M |
| April 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| January 31, 2022 | 0.00 |
| October 31, 2021 | -0.1917M |
| July 31, 2021 | -0.0002M |
| April 30, 2021 | -0.0079M |
| January 31, 2021 | 0.00 |
| October 31, 2020 | 0.0035M |
| July 31, 2020 | -0.0001M |
| April 30, 2020 | -0.0073M |
| January 31, 2020 | 0.00 |
| October 31, 2019 | 0.00 |
| July 31, 2019 | -0.0075M |
| April 30, 2019 | 0.00 |
| January 31, 2019 | 0.00 |
| October 31, 2018 | -0.0413M |
| July 31, 2018 | -0.054M |
| April 30, 2018 | -0.0006M |
| January 31, 2018 | -0.0047M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| InMed Pharmaceuticals, Inc. | 0.00 |
| NervGen Pharma Corp. | -0.0001M |
| Milestone Pharmaceuticals, Inc. | 111.84M |
| Lexaria Bioscience Corp. | -0.0271M |
| Target Group, Inc. (Canada) | -0.0065M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.859M |
| Cash from Financing (Quarterly) | 3.136M |
| Free Cash Flow | -6.997M |
| Free Cash Flow Per Share (Quarterly) | -1.175 |
| Free Cash Flow to Equity (Quarterly) | -3.572M |
| Free Cash Flow to Firm (Quarterly) | -1.854M |
| Free Cash Flow Yield | -241.2% |